Rhenman & Partners Asset Management AB Buys LivaNova PLC, Exact Sciences Corp, Abiomed Inc, Sells Biogen Inc, Medtronic PLC, Gilead Sciences Inc

• New Purchases: EXAS, DERM, MDGL, AIMT, RARX, XLRN, NSTG, QGEN, DVAX, EPZM, SYMC, GOOGL,
• Added Positions: LIVN, ABMD, MGNX, NKTR, AMRN, ESPR, BMRN, CNC, ITCI, XNCR, JAZZ, MRTX, IMMU, VRTX, MYOK, CHRS, ABC, GTHX,
• Reduced Positions: MDT, INCY, EXEL, CELG, ABBV, ALXN, BDX, SAGE, BMY, BLUE, EW, ARNA, FGEN, SGEN, FLXN, CVS, NVCR, SGMO, IOVA, LLY, NBIX, ALKS, HUM, ALNY, AGN, ANTM, ARRY, UNH, AERI, CMRX, REGN, BSX, ABT, GKOS, ACHN, MDCO,
• Sold Out: BIIB, GILD, PTLA, MD, ONCE, ADMS, LH, LOXO,

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to https://www.gurufocus.com/guru/rhenman+%26+partners+asset+management+ab/current-portfolio/portfolio

1. UnitedHealth Group Inc (UNH) - 123,400 shares, 3.57% of the total portfolio. Shares reduced by 2.37%
2. Jazz Pharmaceuticals PLC (JAZZ) - 187,171 shares, 3.13% of the total portfolio. Shares added by 12.88%
3. Vertex Pharmaceuticals Inc (VRTX) - 144,400 shares, 3.11% of the total portfolio. Shares added by 9.04%
4. Abiomed Inc (ABMD) - 92,493 shares, 3.09% of the total portfolio. Shares added by 41.62%
5. Cigna Corp (CI) - 159,691 shares, 3.00% of the total portfolio.

Rhenman & Partners Asset Management AB initiated holding in Exact Sciences Corp. The purchase prices were between $61.98 and $96.5, with an estimated average price of $84.73. The stock is now traded at around $95.15. The impact to a portfolio due to this purchase was 1.01%. The holding were 100,000 shares as of .

Rhenman & Partners Asset Management AB initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $13.70. The impact to a portfolio due to this purchase was 0.79%. The holding were 500,329 shares as of .

Rhenman & Partners Asset Management AB initiated holding in Madrigal Pharmaceuticals Inc. The purchase prices were between $103.48 and $143.84, with an estimated average price of $124.23. The stock is now traded at around $142.50. The impact to a portfolio due to this purchase was 0.4%. The holding were 27,225 shares as of .

Rhenman & Partners Asset Management AB initiated holding in Ra Pharmaceuticals Inc. The purchase prices were between $18.2 and $27.22, with an estimated average price of $21.4. The stock is now traded at around $23.45. The impact to a portfolio due to this purchase was 0.39%. The holding were 150,000 shares as of .

Rhenman & Partners Asset Management AB initiated holding in Aimmune Therapeutics Inc. The purchase prices were between $21.15 and $26.37, with an estimated average price of $23.55. The stock is now traded at around $22.29. The impact to a portfolio due to this purchase was 0.39%. The holding were 149,201 shares as of .

Rhenman & Partners Asset Management AB initiated holding in Acceleron Pharma Inc. The purchase prices were between $39.06 and $48.05, with an estimated average price of $43.83. The stock is now traded at around $44.74. The impact to a portfolio due to this purchase was 0.38%. The holding were 70,000 shares as of .

Rhenman & Partners Asset Management AB added to a holding in LivaNova PLC by 99.50%. The purchase prices were between $86.15 and $100.49, with an estimated average price of $93.42. The stock is now traded at around $69.92. The impact to a portfolio due to this purchase was 1.37%. The holding were 240,600 shares as of .

Rhenman & Partners Asset Management AB added to a holding in Abiomed Inc by 41.62%. The purchase prices were between $276.39 and $362.25, with an estimated average price of $332.72. The stock is now traded at around $280.54. The impact to a portfolio due to this purchase was 0.91%. The holding were 92,493 shares as of .

Rhenman & Partners Asset Management AB added to a holding in Macrogenics Inc by 78.39%. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $18.34. The impact to a portfolio due to this purchase was 0.89%. The holding were 967,186 shares as of .

Rhenman & Partners Asset Management AB added to a holding in Nektar Therapeutics Inc by 42.61%. The purchase prices were between $31.58 and $46.35, with an estimated average price of $39.54. The stock is now traded at around $35.83. The impact to a portfolio due to this purchase was 0.86%. The holding were 734,445 shares as of .

Rhenman & Partners Asset Management AB added to a holding in Amarin Corp PLC by 270.80%. The purchase prices were between $12.61 and $22.33, with an estimated average price of $17.95. The stock is now traded at around $19.46. The impact to a portfolio due to this purchase was 0.66%. The holding were 370,800 shares as of .

Rhenman & Partners Asset Management AB added to a holding in Esperion Therapeutics Inc by 35.54%. The purchase prices were between $40.11 and $53.57, with an estimated average price of $44.86. The stock is now traded at around $42.89. The impact to a portfolio due to this purchase was 0.59%. The holding were 479,767 shares as of .

Rhenman & Partners Asset Management AB sold out a holding in Biogen Inc. The sale prices were between $216.71 and $338.96, with an estimated average price of $315.3.

Rhenman & Partners Asset Management AB sold out a holding in Gilead Sciences Inc. The sale prices were between $62.53 and $70.05, with an estimated average price of $66.46.

Rhenman & Partners Asset Management AB sold out a holding in Portola Pharmaceuticals Inc. The sale prices were between $17.93 and $34.72, with an estimated average price of $28.71.

Rhenman & Partners Asset Management AB sold out a holding in Mednax Inc. The sale prices were between $27.12 and $36.86, with an estimated average price of $33.62.

Rhenman & Partners Asset Management AB sold out a holding in Spark Therapeutics Inc. The sale prices were between $37.95 and $113.98, with an estimated average price of $72.19.

Rhenman & Partners Asset Management AB sold out a holding in Laboratory Corp of America Holdings. The sale prices were between $123.7 and $156.3, with an estimated average price of $143.14.

Rhenman & Partners Asset Management AB reduced to a holding in Medtronic PLC by 43.79%. The sale prices were between $82.45 and $93.79, with an estimated average price of $89.53. The stock is now traded at around $88.63. The impact to a portfolio due to this sale was -1.37%. Rhenman & Partners Asset Management AB still held 168,842 shares as of .

Rhenman & Partners Asset Management AB reduced to a holding in Incyte Corp by 62.46%. The sale prices were between $63.56 and $88.17, with an estimated average price of $81.08. The stock is now traded at around $83.41. The impact to a portfolio due to this sale was -1.21%. Rhenman & Partners Asset Management AB still held 100,000 shares as of .

Rhenman & Partners Asset Management AB reduced to a holding in Exelixis Inc by 55.16%. The sale prices were between $19.6 and $24.76, with an estimated average price of $22.74. The stock is now traded at around $24.19. The impact to a portfolio due to this sale was -1.19%. Rhenman & Partners Asset Management AB still held 430,000 shares as of .

Rhenman & Partners Asset Management AB reduced to a holding in Celgene Corp by 69.54%. The sale prices were between $64.09 and $94.34, with an estimated average price of $87.12. The stock is now traded at around $94.33. The impact to a portfolio due to this sale was -1.1%. Rhenman & Partners Asset Management AB still held 65,698 shares as of .

Rhenman & Partners Asset Management AB reduced to a holding in AbbVie Inc by 63.06%. The sale prices were between $77.14 and $92.19, with an estimated average price of $82.08. The stock is now traded at around $82.95. The impact to a portfolio due to this sale was -1.08%. Rhenman & Partners Asset Management AB still held 60,000 shares as of .

Rhenman & Partners Asset Management AB reduced to a holding in Alexion Pharmaceuticals Inc by 40.78%. The sale prices were between $97.36 and $137.75, with an estimated average price of $123.89. The stock is now traded at around $141.30. The impact to a portfolio due to this sale was -1.04%. Rhenman & Partners Asset Management AB still held 136,466 shares as of .